Posted on Leave a comment

Healthcare June 6 (MRNA GILD AZN MRK PFE ABBV BMY JNJ SRPT UNH)

We’re talking healthcare right now. Madame took off look at this. So this is the two weeks, basically one, two, three, four, five, six, seven, eight, nine. Yeah. That’s two weeks we started and we could go Monday when we bounced on a one 59, we have literally gone 50 points straight up, broke it late. Is that an all time high? Let’s check that out. Yes, it is. It broke out of his three basically triple top with a vengeance headed to two 2215 area. Just cause it blew through this area. I would be looking forward to come back down to the 91 area for some support at that point in time. I think it would be a safer bet if it can hold this to buy it. But this, I mean, you know, the Corona virus and all this other kind of stuff, they’re, they’re one of the first ones that were given the government contract to rapid release or whatever it was called last year by Donald Trump.

So it makes sense why this is blooming. Yeah, I don’t want to go too much else into the company because we’re just looking at the stock chart, but what a beautiful, beautiful explosion right there. Gilly ad sciences. Okay. We are getting to the point where it looking interesting. So this was a Monday, we got pounded into our line, which was great. And then since then I just like a quick $2 gain up into 67. I would watch out for the 67 77. Wait for it to come get rejected, then come back maybe to right around this area. Well, let’s draw a line so we can use for reference next week. I mean, obviously that’s not the most perfect place. I was going to go down maybe 33, four sentence, but it’s close enough. So I would, once it kind of pops here, maybe it looks above fails, comes back down to this line, it holds this line. Then I think it has a higher probability to break out and, and reach for the stars as your tenant, as drought Zeneca. Okay. Look at this.

We had our support. I’m coming down. This really hasn’t moved anywhere. It’s kind of boring. I, it looks like a lot, but it’s really gone. Absolutely Nowhere. So we’re with Him 2 cents or within a dollar. So 57 53 fit or $2 57 or 55 75. So it’s a pretty tight range. I would like to see that there, the moving averages move up, which probably what it’s doing. Cause we, we got, we had our parabolic move when actually we broke above. So this was negative. We broke a bug of 50 and a hundred came back down and touch the 50 while the 50 crossed the 100 and then just went parabolic. So I would say, give me a little bit, let it hold hover. The 55 75, maybe for like another week, week, week and a half. Let our lions can to come back up and then we’ll look for some more upward trajectory.

Yeah, no, I don’t like it. This at all, this is terrible. This is ugly. Completely ugly. I mean, yeah, whatever you had some support, it bounced off a support, two points had a horrible drop, no earnings or anything to it. Just drop out of nowhere. What does, I mean, this is Monday, Tuesday, or this is Tuesday, Wednesday, Thursday, Friday. So I mean, Wednesday, you had an update Thursday, you gapped down like $2. What’s going on with Merck. Any which way I don’t like it, but I wouldn’t for a quick, a couple of points. You could try to fade it up to the 78, 74, 99 before it goes back down. But I don’t know. That’d be really risky on that. Cause you know, it probably wants to fill the gap and it shot down so fast or reversion to the mean would mean that let’s draw this line. So reversion to the mean, see it hit the seven, seven, eight, six retracement perfectly. That’s where it got stopped out reversion to the mean would be all the way back up to 76, 62.

So two points away.

Not really big, but as you can see right here, it in a strong trend, it should hit here and then continue downwards. And the secondary strong trend look at a secondary strong trend before it even hits the 50% tall, six one eight is filling the gap, right? So it could fill the gap and roll back over and it still be bears Pfizer. So we fired short on our a squeeze, but I’m pretty sure the squeeze is going to reactivate, which means that these, these green dots are going to turn back to red dots. I would’ve seen anything negative right here. It basically hit on the 50 perfectly, literally perfectly. I like to see what it does next week. We had a kinda like shooting star on Friday on like this, however, given a little bit it’s kind of right in the middle.

That’s what I’m saying. If it was down here, I’d be like, yeah, it’s by if it’s up here, be like you’re short, but it’s like right in the middle. So I’m not really sure. A B, B V it looks great for a short come down, got up a little bit hitting the nine for the faster downward trend. We just fired long, honest or short on a squeeze. I’ll see. It kind of rolls back over to maybe down to the one oh eight BMY Bristol Myers Squibb. Ah, I don’t like this one looks terrible. However, it is in line with the 50 and we were just making all time highs. So we’re as, as much as it as, as much as I like to say, this looks terrible. We are really only what $3 away from the high is this an all time high.

Okay. From a even larger, this is weekly. Let’s go monthly. So monthly we’re pretty close. We’re 77. So we’re like 13 points away from all time high. We are gaining momentum on a monthly squeeze. This, this is all very positive because we’re in a double squeeze. We’re in the monthly squeeze. We’re also, oh, we just fired long on the weekly squeeze. This is last weekend, this week. So the momentum is telling me that it wants to break this 68 34 it’s four points away. The daily daily daily looks ugly. However, the weekly and the monthly look really bearish or bullish. Excuse me.

Okay. Johnson and Johnson. Yeah. Fired short. Looks like we’re headed to at least one 62, right? Unless it, if it can hold this line. I, which I’d be surprised. Cause it just got rejected. Have a low bar, a lot of resistance at the one 66. So I see us crashing down to at least a yellow line. Sarepta therapeutics. Yeah. This is terrible. How ugly can you get? This is just nasty. I don’t like anything about it. We just fired short. Right? So hopefully we can hold the 6,804, right? You’re knighted health group building momentum to squeeze downward. There’s just, I don’t know. It’s holding a four oh four if it holds a four oh four for another week. Right. Cause if that’s what it’s kind of looking like on Thursday, we broke below just recently, just barely. But again, it looks like we’re just holding for the, the moving averages to come and meet up to the price opposed to coming down or like having liquidation down. It looks like they’re just, they’re holding it as tight as possible to bring them the moving averages higher. If that’s the case, look for upward trajectory. All right. That’s healthcare.

Portfolio

Energy June 28 (VLO XOM MMP SUN RDSA E KMI BP TOT CVX /CL)

(adsbygoogle = window.adsbygoogle || []).push({}); Portfolio

Keep reading

Financials June 28 BLK GS FAS CME NTRS TROW SCHW BAC KKR BX

(adsbygoogle = window.adsbygoogle || []).push({}); Portfolio

Keep reading

Basic Materials June 28 (SMG ECL LYB DD DOW BASFY RIO IP MOS SHW)

(adsbygoogle = window.adsbygoogle || []).push({}); Portfolio

Keep reading

Utilities June 28 NRG DUK DTE MSEX BEP NOVA AES IDA AKW RSG

(adsbygoogle = window.adsbygoogle || []).push({}); Portfolio

Keep reading

Energy June 20 (VLO XOM MMP SUN RDSA E KMI BP TOT CVX /CL)

(adsbygoogle = window.adsbygoogle || []).push({}); Portfolio

Keep reading

Financials June 20 BLK GS FAS CME NTRS TROW SCHW BAC KKR BX

(adsbygoogle = window.adsbygoogle || []).push({}); Portfolio

Keep reading

Basic Materials June 20 (SMG ECL LYB DD DOW BASFY RIO IP MOS SHW)

(adsbygoogle = window.adsbygoogle || []).push({}); Portfolio

Keep reading

Utilities June 20 AWK MSEX IDA DUK RSG NRG DTE NOVA AES BEP

(adsbygoogle = window.adsbygoogle || []).push({}); Portfolio

Keep reading

Utilities June 14 NRG DUK DTE MSEX BEP NOVA AES IDA AWK RSG

So we got NRG, which is, I mean, if remember…

Keep reading

Basic Materials June 14 (SMG ECL LYB DD DOW BASFY RIO IP MOS SHW)

basic materials. Scott’s miracle grow. This has been in the…

Keep reading

Financials June 14 (FAS KKR BAC SCHW BLK TROW GS BX NTRS CME)

All right with financials. We’ll start with CME. Now. Most…

Keep reading

Energy June 14 (VLO XOM MMP SUN RDSA E KMI BP TOT CVX /CL)

All right. For our first energy stock, we have Valero…

Keep reading

Utilities June 6 Nova AWK RSG BEP IDA AES DUK MSEX DTE NRG

Okay for utilities. Our first stock is a Nova, which…

Keep reading

June 6 Basic Materials (ECL RIO SHW IP DD BASFY SMG DOW LYB MOS)

Basic materials. We have Ecolab Ecolab looks like we’re finally…

Keep reading

Energy June 6 (CVX MMP XOM E KMI TOT RDSA VLO SUN BP)

About this further, last few weeks, Months, whatever it is.…

Keep reading

June 6 Financials (BLK TROW GS BX FAS CME BAC KKR SCHW NTRS)

Financials. Well, I call banking, but whatever financials are, first…

Keep reading

Healthcare June 6 (MRNA GILD AZN MRK PFE ABBV BMY JNJ SRPT UNH)

We’re talking healthcare right now. Madame took off look at…

Keep reading

May 31 Energy CVX MMP SUN KMI TOT BP E XOM RDS VLO

We have energy If we look at oil, if you’ve…

Keep reading

Basic materials May 31 SMG BASF MOS DD DOW RIO IP LYB ECL SHW

Basic materials. Scott’s miracle grow One, two, three, four, five,…

Keep reading

May 31 Financials (GS TROW CME BLK BX FAS SCHW KKR BAC NTRS)

Excuse me. We start with financials. Look, this is Goldman…

Keep reading

May 31 Utilities AWK MSEX IDA DUK RSG NOVA AES DTE NRG BEP

We have American water, which is basically right up to…

Keep reading

Healthcare May 31 MRNA ABBV JNJ GILD PFE BMY MRK AZN UNH SRPT

Or excuse me for healthcare first, go over Minera or…

Keep reading

May 23 Utilities (AWK DUK DTE BEP IDA RSG AES NOVA MSWX NRG)

Video, we’ll go over utilities. This is  AWK American water.…

Keep reading

Energy May 23 (CVX SUN VLO TOT RDSA E XOM KMI BP MMP)

Energy, if will, same story kind of washing the repeat…

Keep reading

Healthcare May 23 (UNH BMY AZN JNJ PFE MRK GILD SRPT ABBV MRNA)

All right. We got healthcare. Well, dare does. This is…

Keep reading

Basic Materials May 23 (LYB IP DOW SHW MOS DD BASF ECL RIO SMG)

Basic materials. Let’s go ahead and get into our accounts.…

Keep reading

Financials May 23 (BLK GS FAS TROW CME NTRS BX SCHW BAC KKR)

The banking sector or, you know, finance financials. We got…

Keep reading

Healthcare May 16 (MRNA, SRPT, UNH, JNJ, AZN, PFE, BMY, ABBV, GILD, MRK)

All right. Healthcare starting off with Merck and co. Yeah.…

Keep reading

Utilities May 16 (NOVA, BEP, AES, DTE, AWK, MSEX, NRG, DUK, IDA)

Go over today is the utilities list. Now last week…

Keep reading

Basic Materials May 16 (LYB, ECL, MOS, DOW, DD, SMG, SHW, IP, BASFY, RIO)

We got LyondellBasell this is, this looks pretty good. What…

Keep reading

Something went wrong. Please refresh the page and/or try again.

Healthcare

Gilead Sciences:

Over Five Years They Were Really Popular In 2015 But As Of Right Now They’re Kind…

Keep reading

Abbvie:

Is A Biopharmaceutical Company Founded In 2013. Its Original Company Was Abbott Laboratories But They Decided…

Keep reading

Astrazeneca:

They Have 172 Projects In Their Pipeline, 9 New Molecular Entries In Their Late Stage Pipeline…

Keep reading

Merck:

Merck Stock Ticker Mrk. Over The Last Five Years The Stock Price Has Consistently Gone Higher.…

Keep reading

Moderna:

Moderna Stock Ticker Mrna. If We Analyzed Their Stock Price Over The Last 10 Years Or…

Keep reading

Bristol-Myers Squibb:

Their Main Focus Is Research And Therapeutic Areas Where They Believe They Can Deliver Transformational Medicines…

Keep reading

Sarepta Therapeutics:

Sarepta Therapeutics Stock Ticker Srpt. This Company Is At All-Time High Over The Last 5 Years…

Keep reading

Johnson & Johnson:

Johnson & Johnson Can Be Broken Up Into Three Different Departments; Consumer Health Products, Medical Devices,…

Keep reading

UnitedHealth Group:

Unitedhealth Group Stock Ticker Unh. Over The Past Five Years This Company Has Traditionally Gone Higher.…

Keep reading

Something went wrong. Please refresh the page and/or try again.

Crypto

Chevron Corp (CVX) or Algorand (ALGO )or DAI what is the most profitable investment

This Coinbase is offering me another $3 just to watch…

Keep reading

Coinbase Gave Me 6$ For Watching A Video

Yes, earn some compound by just watching the video. So…

Keep reading

Still Don’t Know What They Are Talking About Matic But Was Given A Couple of Dollars To Be Confused

Polygon where’s that? Oh, we actually have to work for…

Keep reading

Make 3$ In 3 Minutes Learning About The Graph With Coinbase

I’m almost done with my peanuts kind of. Nope. That…

Keep reading

Coinbase Paid me 8 Dollars Worth Of XLM For Watching Videos

We have energy If we look at oil, if you’ve…

Keep reading

ANKR

the only reason I’m looking at this is I’m making…

Keep reading

Making Compound interest With Algorand

Yo yeah, if this is added money, this right here,…

Keep reading

Non-Believer To A Believer

I get into my review for stocks, as opposed to…

Keep reading

Tezos Better Buy Than Algorand

The quick video. I mean, nothing too exciting. However, the…

Keep reading

Coinbase Web Overview

Good since I’m just now getting started in cryptocurrency, that…

Keep reading

Decentraland

All right, let’s jump into this. That’s fine. Another coin…

Keep reading

Litecoin

Let’s talk about a different crypto coin or currency, however…

Keep reading

Storj

Door storage. Yeah, I guess. Right. Um, they just offered…

Keep reading

Tezos

Um, you see the accounts getting a little bit bigger.…

Keep reading

SushiSwap

Let’s check in a little bit more on cryptocurrency. That’s…

Keep reading

Making A Couple Dollars On Coinbase

So let’s discuss the rewards that Coinbase allows you to…

Keep reading

Stable Coins

why will you use a stable coin if you were…

Keep reading

Ethereum

Got it again, we are on Coinbase. Let’s pick another…

Keep reading

Cardano

It’s a tiny little one, a dollar and 20 cents,…

Keep reading

Earning Interest Through Crypto

earning interest through crypto Video. We’re going to dive a…

Keep reading
Posted on Leave a comment

Healthcare May 31 MRNA ABBV JNJ GILD PFE BMY MRK AZN UNH SRPT

Or excuse me for healthcare first, go over Minera or Moderna Moderna had an amazing day on Friday, 3%. Let’s check out this last week. Yeah. The moves just got bigger and bigger and bigger and bigger and huge. So this is, oh, Darren. I popped off of the 50 then held the the one, five, nine to 50% retracement or extension. And it looks like it’s off for the races. Well, we got one 86 watch a quick little, one 91 pop or like basically drop. I would say it dropped like all the way down to maybe 72. It could cause liquid came from, from, you know, 59.

But if we hit the [inaudible], I’d say it comes back down to right around here. The 80 level that the 80 level I’d say by a good right here would have been your ideal jump in, especially after a down day on Friday, but looks good. like I said, be careful. we’re at basically all time highs at the one 89 or the yearly highs at one 99, which is basically all time highs for the stock. So be very careful. This could just take off, hit the two 15 and then shake everybody out. Remember just, just think of all the different possibilities that could happen. We are coming up to a massive amount of resistance, which is here and here. So we break out, we can break out pretty decent.

A B, B V we’re just entered the squeeze as you could, as an indication down here. I don’t know. I’m not, not, I guarantee that I’ve really liked this the way it is. Yes. We just hit the 50. So it would be a, a textbook just by, and obviously we’ve got the bounce the next day, but then we got rejected right at the 20. So I, if it holds the 50, great let’s look for it to, to kind of shift back up to one 19. But if not it could just drop down to the 100, which would be one oh eight. So just be careful. I, it doesn’t look very pretty Johnson and Johnson. We are right at the highs high end tight Friday started off great, kinda got destroyed. As you can see this chart doesn’t even, it doesn’t even tell justice. It looks extremely barest right here, but when you put it all in perspective, it’s a two point difference on a hundred dollars stock. So we’re looking at like nothing, 2% difference. No, it’s almost $200 stocks, like one and a half percent difference between here and where we are. So it’s not very much. And we’ve been dancing around in here for quite some time as we just entered a squeeze. So I, I mean, it’s all kind of goes and see what happens with the market, but I don’t see any problem with this at all.

Okay. However, let me say before, I would really want to get in. I want to see it go above the one 71 or if it kind of touches down at the 50 kind of the one 66, I would say that’d be another decent entry, but I’d be careful because it could flush further, but I wanted to see if it can maintain

Holding the 66 75 gild

This got, just look at this now I know I was saying, be careful watch the 67, but wow. I mean, that’s not really that much. It’s 66, so it’s not like it really dropped terribly, just looks terrible on them on the chart. Again, looks terrible on a chart, but we’re right at the 50 holding the hundred. Here’s three easy. If we can get to, if we hold this for maybe next week and we’re anywhere between this area, you know, went down, touched it and then starting to build higher then. Yeah. I’d want to get in looking forward to break the 67 77 and go higher than the 70. Or if this just starts going up next week, I’d want to see it break the 67, hold the 67, then go from there. Pfizer

Well, last week was not very helpful for Pfizer and we’re in a downward squeeze at this moment. I’m rising. Yeah. Stay away. Unless you want a short, I’d say this is a short, but watch be very careful because we have the 50, which we have all these lines right here. There is with support from the past, or just be very careful, but it does not look like Pfizer’s going To.

Doesn’t look like it’s going to the moon. Let’s just say that might be going downward. Bristol Myers, man. It’s like all the healthcare. We broke it out, which was one, two, three, four, five, and Monday we broke it to a high and God destroyed, but we were at the 20. So let’s see what that does on the 20th. It owes the 20th and look forward to break out. Cause this are dyadic stitches. These are just like I drew. So we’re in their range. As you see, is, is they’re high and a high, so we hold, hold this, this green line and look for it to go higher if it holds

Merck.Oh yeah, this is nasty. Ah, last week was a terrible week for this for Merck. And as the chart looks, doesn’t look like it’s getting any time and we’re better. So yeah, short by some bullets, AstraZeneca. I like it just be easy. It could jiggle around a little bit longer for the 20 to break the 55 75. This could. So in other words, we couldn’t hit the 70 or the 55 75 just to make sure the green go through Babette there decided to go higher. Yeah. H U N H United health group just well entered to squeeze two days ago. It says negative momentum. I would like to disagree with that. It looks like we’re steady building a little bit higher and a little bit higher looking to break the four 25. So if I were, I would buy some calls maybe a little bit longer or we’ll give it a little bit of time, but that’s going to be, that will be expensive just because it’s a $400 stock. No Sarepta Sarepta Yeah, it looks like a rollback over who were retest this 68 zero four. All right. Healthcare.

Portfolio

Healthcare

Pfizer:

Over The Last 5 Years This Company Has Been Pretty Stagnant It Consistently Pays Dividends But…

Keep reading

Crypto

Posted on

Gilead Sciences:

Over Five Years They Were Really Popular In 2015 But As Of Right Now They’re Kind Of Going Down Institutional Ownership 80% I Do Like That, They Are Making A Lot Of Money From Remdesivir, This Drug Was Approved As An Emergency Treatment In Hospitals. They Originally Created This Drug To Help Fight Against Ebola. Since This Is A Repurposed Drug The Costs Associated With Production Are Very Low. They Recommended A 5-Day Treatment With A Value Of 2300$ The Cost To The Company Per Five-Day Treatment Is 5$. These Numbers Are Rounded To The Nearest Whole Number, However As We See They Are Making Close To 2295$ Per Covid19 Hospital Treatment. Remdesivir Is Approved In Australia, Canada, The European Union, Japan, And The United States.

The Company Is At A Seven-Year Low, However, They Have Consistently Been Able To Pay About 4% Annual Dividend.

In Other News, They Signed An Agreement To Provide 200K Prescriptions Of Their Hiv Drug For 11 Years For Free To The Recipient But The Government Will Reimburse Them 200$ Per 30 Pills.

Posted on

Abbvie:

Is A Biopharmaceutical Company Founded In 2013. Its Original Company Was Abbott Laboratories But They Decided To Break Abbott Laboratories Into Two Different Publicly Traded Companies So Investors Would Be Able To Value The Company Separately With Abbott Laboratories Specializing In Diversified Products Including Medical Devices, Diagnostic Equipment And Nutrition Products And Abbvie Would Operate As A Research-Based Pharmaceutical Manufacturer.

Their Ventures Team Is Comprised Of Seven Investment Professionals Across Three Major Us Locations Cambridge Massachusetts Chicago Illinois And San Francisco California.

The Company’s Main Focus Areas Are Immunology, Oncology, Neuroscience, Women’s Health, Platforms And Technology, Cystic Fibrosis And Virology.

One Of Their Largest And Most Profitable Acquisitions To Date Happened May 8Th 2020 When They Completed The Acquisition Of Allergan. By Buying Allergan They Have Bought A Well-Seasoned Pipeline Of Different Products Already Available On The Market Such As Botox.

Posted on

Astrazeneca:

They Have 172 Projects In Their Pipeline, 9 New Molecular Entries In Their Late Stage Pipeline And One New Molecular Entry To Registration,

The Therapy Areas Astrazeneca Is Focused On Are Oncology, Cardiovascular, Renal & Metabolism, Respiratory And Immunology. They’re Also Discovering Different Solutions To More Of Life’s Problems Such As Diabetic Neuropathy, Parkinson’s Disease, Alzheimer’s Disease, Opiate Use Disorder And The Prevention Of Nosocomial Staphylococcus Aureus Pneumonia. 

They Have Three Major Locations With One In Gaithersburg Maryland This Campus Employees More Than 3,000 Experts. Their Second Location Is In Gothenburg Sweden With More Than 2,400 Employees From 50 Different Countries. And Their Main Location Located In Cambridge United Kingdom. Boasting That Cambridge Is One Of The Most Exciting Bioscience Locations In The World Providing Over 19,000 Local Jobs And More Than 440 Life Science And Health Care Organizations. 

Posted on

Merck:

Merck Stock Ticker Mrk. Over The Last Five Years The Stock Price Has Consistently Gone Higher. It Looks As If The All-Time High Was At The Beginning Of 2020. Since Coronavirus Happened It Has Regained Most Of The Coronavirus Drop But It Has Yet To Break Out Of All-Time Highs. The Institutional Ownership Is At 75% Which Is A Little Lower Than I Like To See Which Is At 80%.

The Company Operates In Four Segments Pharmaceutical, Animal Health, Healthcare Services, And Alliances. Their Vaccine Products Consists Of Prevented Pediatric, Adolescent And Adult Vaccines. Merck Pays 3.3% Dividend Annually.

Posted on

Moderna:

Moderna Stock Ticker Mrna. If We Analyzed Their Stock Price Over The Last 10 Years Or 5 Years You Will See That They’ve Been Under A $30 Company Until The Beginning Of This Year. What Is Very Interesting About This Company Is Since Inception Which Was 2018 This Company Has Lost 1.5 Billion Dollars And They Lost 500 Million Alone In 2019. In Early 2020 The Ceo Of Moderna Told The President That They Would Be Able To Have A Vaccine For Coronavirus And Since Then Their Stock Has Went From Under $25 To Over $130. The Company Was Awarded Over Four Hundred Million Dollars From Operation Warp Speed To Bring A Solution Or Vaccine To The Market. This Company Does Not Pay A Dividend. Institutional Ownership For This Stock Is Quite Low At 52%. What Concerns Me The Most About This Company Is Days Before The Government Approved Their Coronavirus Vaccine It Is Seen In Their Sec Filings, Many Of The Top Directors Of The Company Sold Their Stock, The Ceo Of The Company In One Transaction Turned $400,000 Into 13 Million Dollars. It Raises The Question If You Believed In Your Company And The Products Why Would You Cash Out At The Beginning Of The Ride. To Me The Only Reason Someone Would Cash Out Millions Of Dollars Is They Are Not A Firm Believer In Their Product Or Their Company And It Sounds Like A Traditional Pump And Dump.

Posted on

Bristol-Myers Squibb:

Their Main Focus Is Research And Therapeutic Areas Where They Believe They Can Deliver Transformational Medicines To Patients. Right Now They Are Studying More Than 40 Different Diseases And They Have Over 50 Compounds In Development. 

Translational Medicine: 

This Is A Rapidly Growing Discipline In The Biomedical Research Its Purpose Is To Expedite The Discovery Of New Diagnostic Tools And Treatments. With Their World Class Researchers And Their Long History Of Translating Scientific Learning Bristol-Myers Squibb Strives To Uncover Life-Changing Treatments For The Most Challenging Diseases Of Now And The Future. 

Through Their Research And Development Division They’re Looking To Develop Drugs For Solid Tumors, Lung Problems, Head And Neck Issues, Esophageal, Gastroesophageal, Glioblastoma, To Name A Few. 

A Notable One Of Its Subsidiaries Is Celgene Corp. Celgene Is A Pharmaceutical Company That Makes Cancer And Immunology Drugs Their Major Product In Their Pipeline Is Revlimid.

Posted on

Sarepta Therapeutics:

Sarepta Therapeutics Stock Ticker Srpt. This Company Is At All-Time High Over The Last 5 Years You Can See It’s Out Of Trouble Breaking Out Of The 150 Level But Since Is That 175 During The Corona They Dipped Slightly But Reached An All-Time High Before July Then Dipped And In December Sarepta Is Once Again At An All-Time High. 

This Company Would Be Classified More As A Growth Stock Since It Does Not Pay Dividends. Sarepta Therapeutics Is A Biopharmaceutical Company That Focuses On Discovery And Development Of Ribose Nucleic Acid (Rna)-Targeted Therapeutics Which Is The Treatment Of Rare Neuromuscular Diseases. 

The Company Is Located In Cambridge Massachusetts The Institutional Ownership Of This Company Is Quite High At 92% 

Posted on

Johnson & Johnson:

Johnson & Johnson Can Be Broken Up Into Three Different Departments; Consumer Health Products, Medical Devices, And Pharmaceutical Products. 

Consumer Health Products :

Their Products Are In Almost Every Convenient Or Grocery Store Across The United States Their Brands Help People Live Healthier Lives Through Skin Health Products, Self Care

Products, And Essential Health Products,

 Skin Health Products :

  A Few Of Their Skin Health Products Are Neutrogena Which Has Been Bringing Customers Skin Care Solutions For More Than Sixty Years Is Available In More Than 70 Countries, Aveeno Which Is Available In 22 Countries Worldwide, Dr.Ci:Labo Was Founded By Renowned Japanese Dermatologist Dr. Yoshinori Shirono In 1999.

 Self Care Products:

   If You’ve Ever Needed To Use Tylenol, Motrin, Zyrtec, Or Benadryl, Even Nicorette You Are Using A Johnson & Johnson Product. Those Are Just A Few To Name In Johnson Johnson’s Arsenal Of Self Care Products. 

Essential Health Products:

For 125 Years Johnson & Johnson Has Provided Gentle Products For Babies And Adults If You’ve Ever Needed A Band-Aid A Recognizable Brand Band-Aid Is Also A Johnson & Johnson Product. A Mouthwash That Has Been Used Over A Billion Times And Is In 85 Different Countries Is Also A Johnson & Johnson Product By The Name Of Listerine. 

Medical Devices:

The Always Changing Environment Johnson & Johnson Are Making The Correct Connections Across Science And Technology To Combine Their Expertise In Vision, Orthopedics, Interventional Solutions, And Surgery.

Pharmaceutical Products

 In Johnson & Johnson’s Labs They Address Some Of The Most Devastating And Complex Diseases Known To Man. Their Pharmaceutical Company Is Janssen Pharmaceutical Companies Their Main Purpose Is Changing The Way Diseases Are Prevented Intercepted Treated And Cured. Diseases That They Focus On Are; Immunology, Cardiovascular & Metabolic Disease, Pulmonary Hypertension

Infectious Diseases & Vaccines, Neuroscience, And Oncology